Last reviewed · How we verify

NCT05747937

Longitudinal Assessment of Autonomic and Sensory Nervous System in ALS

Recruiting now NA Last updated 17 April 2026
What this trial tests

NA trial testing Skin biopsy in Amyotrophic Lateral Sclerosis in 100 participants. Currently enrolling.

Timeline
15 May 2021
Primary endpoint
30 September 2026
30 December 2026

Quick facts

Lead sponsorIstituti Clinici Scientifici Maugeri SpA
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment100
Start date15 May 2021
Primary completion30 September 2026
Estimated completion30 December 2026
Sites2 locations across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Istituti Clinici Scientifici Maugeri SpA

Who can join

18 and older, any sex, with Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this interventional non-pharmacological study is to evaluate, using a multimodal approach, the progression of autonomic and sensory involvement in in amyotrophic lateral sclerosis (ALS) patients enrolled within 18 months from motor onset and its relationship with the progression of overall clinical disability. The main questions it aims to answer are: * Is autonomic dysfunction at diagnosis associated with disease progression and survival in patients with Amyotrophic Lateral Sclerosis ? * Can we identify in the skin biomarkers to be used as reliable measures of disease progression and to apply in future clinical trials for patient stratification and to assess response to drug treatment ? Participants at time 0 will receive a full clinical and instrumental examination and a blood sample testing to check inclusion and exclusion criteria, genetic screening for the most common genes associated with ALS (SOD1, FUS, TARDBP and c9orf72), questionnaires about clinical characteristics, quality of life, pain and a multidomain battery of neuropsychological tests, multimodal assessment of the autonomic nervous system including skin biopsy for morphological study. At follow-up we'll perform clinical scales and skin biopsy. Researchers will compare results from ALS patients with data obtained from a population of age and sex matched healthy subjects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Neurophysiologic Innovations in ALS: Enhancing Diagnosis, Monitoring, and Treatment Evaluation.
    Donaghy R, Pioro EP. · · 2024 · cited 2× · PMID 39766450 · DOI 10.3390/brainsci14121251

Verify or expand the search:

Other trials of Skin biopsy

Trials testing the same drug.

Other recruiting trials for Amyotrophic Lateral Sclerosis

Currently open trials in the same condition.

Other Istituti Clinici Scientifici Maugeri SpA trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05747937.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing